← All trials
NCT02757625
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 20, 2016
- Primary completion
- May 24, 2017
- Completion date
- May 24, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 63
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- PfizerLead sponsor
- PfizerStudy director
- Maruishi PharmaceuticalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.